Protalix BioTherapeutics (PLX) Raw Materials (2011 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Raw Materials of $6.0 million for Q1 2026, up 33.97% year-over-year from $4.5 million in Q1 2025, and little changed quarter-over-quarter from $6.0 million in Q4 2025.
Protalix BioTherapeutics (PLX) Raw Materials (2011 - 2026) Analysis & Trends
Protalix BioTherapeutics' Raw Materials history runs 11 years deep, the most recent figure standing at $6.0 million for Q1 2026.
- In Q1 2026, Raw Materials rose 33.97% year-over-year to $6.0 million; the TTM figure through Mar 2026 stood at $6.0 million (up 33.97% YoY), while the FY2025 annual figure was $6.0 million, up 31.46% from the prior year.
- Raw Materials for Q1 2026 stood at $6.0 million, roughly flat from $6.0 million in the prior quarter.
- The five-year high for Raw Materials was $6.0 million in Q1 2026, with the low at $3.1 million in Q1 2022.
- The 5-year median for Raw Materials is $4.3 million (2024), against an average of $4.3 million.
- The sharpest annual moves came in 2022 and 2023: Raw Materials declined 10.53% in 2022, then surged 40.51% in 2023.
- Protalix BioTherapeutics' Raw Materials stood at $3.5 million in 2022, then grew by 19.04% to $4.2 million in 2023, then gained by 8.93% to $4.5 million in 2024, then soared by 31.46% to $6.0 million in 2025, then rose by 0.45% to $6.0 million in 2026.
- Business Quant data shows PLX's Raw Materials at $6.0 million in Q1 2026, $6.0 million in Q4 2025, and $5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Protalix BioTherapeutics | 190.37 Mn | 149.71 Mn | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.08 Mn |
| Mar 31, 2026 | 6.01 Mn |
| Dec 31, 2025 | 5.98 Mn |
| Sep 30, 2025 | 4.98 Mn |
| Jun 30, 2025 | 4.36 Mn |
| Mar 31, 2025 | 4.48 Mn |
| Dec 31, 2024 | 4.55 Mn |
| Sep 30, 2024 | 4.24 Mn |
| Jun 30, 2024 | 4.30 Mn |
| Mar 31, 2024 | 4.02 Mn |
| Dec 31, 2023 | 4.18 Mn |
| Sep 30, 2023 | 4.20 Mn |
| Jun 30, 2023 | 4.35 Mn |
| Mar 31, 2023 | 4.31 Mn |
| Dec 31, 2022 | 3.51 Mn |
| Sep 30, 2022 | 3.66 Mn |
| Jun 30, 2022 | 3.30 Mn |
| Mar 31, 2022 | 3.07 Mn |
| Dec 31, 2021 | 3.17 Mn |
| Sep 30, 2021 | 3.17 Mn |